Diabète sucré et stress oxydant

Annales de Biologie Clinique

Volumn 57, Issue 4, 1999, Pages 437-444

  Delattre, J ^a   Bonnefont Rousselot, D ^b   Bordas Fonfrede M ^a   Jaudon, M C ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT;

BLOOD; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; HUMAN; LIPID PEROXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANTIOXIDANTS; BLOOD GLUCOSE; DIABETES MELLITUS; GLYCOSYLATION; HUMANS; LIPID PEROXIDATION; OXIDATIVE STRESS;

EID: 0000598113     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Giugliano D, Ceriello A. Oxidative stress and diabetic vascular complications. Diabetes Care 1996 ; 19 : 257-67.
2. Giardino I, Edelstein D, Brownlee M. BLC-2 expression antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 1996 ; 97 : 1422-8.
3. Ceriello A, dello Russo P, Amstad P, Cerutti P. High glucose induces antioxidant enzymes in human endothelial cells in culture. Evidence linking hyperglycemia and oxidalive stress. Diabetes 1996 ; 45 : 471-7.
4. Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biocliem J 1988 ; 256 : 205-12.
5. Hunt JV, Smith CCT, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990 ; 39 : 1420-4.
6. Cillery P, Monboisse JC, Maquart FX, Borel JP. Glycation of proteins as a source of Superoxide. Diabetes Metab 1988 ; 14 : 25-30.
7. Sakurai T, Tsuchiya S. Superoxide production from non-cnzymatically glycated proteins. FEBS Lett 1988 ; 236 : 406-10.
8. Kennedy AL, Lyons TJ. Glycation, oxidation and lipoxidation in the development of diabetic complications. Metabolism 1997 ; 46 : 14-21.
9. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991 ; 40 : 405-12.
10. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, N epsilon-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996 ; 271 : 9982-6.
11. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radie Biol Med 1994 ; 16 : 383-91.
12. Greene DA, Stevens MJ. The sorbitol-osmotic and sorbitolredox hypotheses. In : Diabetes Mellitus. D. Le Roith, S.I. Taylor and J.M. Olefsky, Eds, Lippincott - Raven Publishers, Philadelphia, 1996.
13. Bucala R, Tracey KJ, Cerami A. Advanced gljcosylation products quench nitric oxide and mediate defective endothelium-depcndent vasodilation in experimental diabetes. J Clin Invest 1991 ; 87 : 432-8.
14. Lefevre G, Beljean-Leymarie M, Beyerle F, et al. Evaluation de la peroxydation lipidique par le dosage des substances réagissant avec l'acide thiobarbiturique. Ann Biol Clin 1998 ; 56 : 305-19.
15. Gallou G, Ruelland A, Campion L, et al. Increase in thiobarbituric acid reactive substances and vascular complications in type 2 diabètes mellitus. Diabètes Metab 1994 ; 20 : 258-64.
16. Greismacher A, Kindhauser M, Ändert SE, et al. Enhanced serum levels of thiobarbituric-acid reactive substances in diabetes mellitus. Am J Med 1995 ;98:469-75.
17. Vijayalingam S, Parthibai, Shanmugasundaram K, Mohan V. Abnormal antioxidant status in unpaired glucose tolerance and noninsulin-dependent diabetes mellitus. Du;« Med 1996 ; 13 : 715-9.
18. Akkus I, Kalak S, Vural H, et al. Leukocyte lipid peroxidation, Superoxide dismutase, glutathione peroxidase and serum and leukocyte vitamin C levels of patients with type II diabetes mellitus. Clin Chiin Acui 1996; 244: 221-7.
19. Santini SA, Marra G, Giardina B, et al. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 1997 ; 46 : 1853-8.
20. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 1995 ; 44 : 1054-8.
21. Childs RE, Badsk WG. The steady-state kinetics of peroxidase with 2, 2'-azino-di- (3 ethyIbenzthiazoline-6 - sulphonic acid) as chromogen. BiochemJ 1975; 145:93.
22. Brasseur L, Thérond P, Legrand A. Pouvoir antioxydant total du plasma. Act Pliarm Biol Clin 1995 ; 8 : 239-44.
23. Cerellio A, Bortolotti N, Pirisi M, et al. Total plasma anti-oxidant capacity predicts thrombosis-prone status in NIDDM patients. Diabetes Care 1997; 20: 1589-93.
24. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994 ; 43 : 1010-4.
25. Cerellio A, Bortolotti N, Crescentini A, et al. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulindependent diabetic subjects. EurJ Clin lin-est 1998 ; 28 : 329-33.
26. Tribe RM, Poston L. Oxidative stress and lipids in diabetes : a role in endothelium vasodilator dysfunction ? Vase Med 1996 ; 1 : 195-206.
27. Hughes K, Choo M, Kuperan P, Ong CN, Aw TC. Cardiovascular risk factors in non-diabetic controls : a population-based survey among Asians in Singapore. Atherosclerosis 1998 ; 136 : 25-31.
28. Kunisaki M, Umeda F, Inoguchi T, Watanabe J, Nawata H. Effects of vitamin E administration in diabetes mellitus. Diabetes Res 1990; 14: 37-42.
29. Caye-Vaugien C, Krempf M, Lamarche P, Charbonnel B, Fieri J. Determination of alpha-tocopherol in plasma, platelets and erythrocytes of type I and type II diabetic patients by higher performance liquid chromatography. Int J ltam Nntr Res 1990 ; 60 : 324-30.
30. Kagan VE, Serbinova EA., Forte T, Scita G, Packer L. Recycling of vitamin E in human low density lipoproteins. J Lipid Res 1992 ; 33 : 385-97.
31. Asayama K, Uchida N, Nakane T, et al. Antioxidants in serum of children with insulin-dependent diabetes mellitus. Free Radie Dial Mcd 1993; 15:597-602.
32. Armstrong AM, Chestnutt JE, Gormley MJ, Young IS. The effect of dietary treatment on lipid peroxidation and anlioxidant status in newly diagnosed non-insulin dependent diabetes. Free Radie Biol Med 1996 ; 21 1119-26.
33. Jain SK, McVie R. Effect of glycémie control, race (white versus black) and duration of diabetes on reduced glutathione content in erythrocytes of diabetic patients. Metabolism 1994 ; 43 : 306-9.
34. Aria K, lizuka S, Tada Y, Oikawa L, Taniguchi N. Increase in the glucosylated form of the erythrocyte Cu-Zn-superoxide dismutase in diabetes and close association of the non-enzymatic glucosylation with the enzyme activity. Biochim BiophysActa 1987 ; 924 : 292-6.
35. Beaudeux JL, Guillausseau PJ, Peynet J, et al. Enhanced susceptibility of low-density lipoprotein to in vitro oxidation in type 1 and type 2 diabetic patients. Clin ChimActa 1995 ; 239 : 131-41.
36. Gugliucci A, Menini T, Stahl AJC. Susceptibility to copper-enhanced autoxidation of VLDL+ LDL fractions from diabetic patients. Biodiem Mol Dial lut 1994 ; 32 : 139-47.
37. Taus M, Ferretti G, Curatola G, Dousset N, Solera ML, Valdiguié P. Lower susceptibility of low density lipoprotein to in vitro oxidation in diabetic patients. Biochem Int 1992 ; 28 : 835-42.
38. Jenkins AJ, Klein RL, Chassereau CN, Hermayer KL, Lopes-Virella MF. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes 1996 ; 45 : 762-7.
39. Jain SK, McVie R, Jaramillo JJ, Chen Y. Hyperketonemia (acetoacetate) increases the oxidizability of LDL + VLDL in type I diabetic patients. Free Radie Biol Mecl 1998 ; 24 : 175-81.
40. Picard S, Talussot C, Serusclat A, Ambrosio N, Benhezene F. Minimally oxidized LDL as estimated by a new method increase in plasma of type 2 diabetic patients with atherosclerosis or nephropathy. Diabetes Melab 1996 ; 22 : 25-30.
41. Lyons TJ, Jenkins AJ. Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol 1997 ; 8 : 174-80.
42. Lopes-Virella MF, Virella G. Cytokines, modified lipoproteins, and arteriosclerosis in diabètes. Diabètes 1996 ; 45 : S40-4.
43. Bellomo G, Moggi E, Poli M, Agosta F, Bollati P, Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabètes 1995 ; 44 : 60-6.
44. Delattre J, Bonnefont-Rousselot D. Oxidative stress, free radicals and aging. In : Biologie prospective. Compte-rendus du 9e Colloque international de biologie prospective de Pont-à-Mousson. MM. Galteau, P. Delwaide, G. Siest and J. Henny, Eds., John Libbey Eurotext, Paris, 1997, pp. 197-203.
45. Dandona P, Thusu K, Cook S, et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996 ; 347 : 444-5.
46. Collins AR, Raslova K, Somorovska M, et al. DNA damage in diabètes : correlation with a clinical marker. Free Radie Biol Hied 1998 ; 25:373-7.
47. Jain SK, McVie R, Jaramillo JJ, Palmer M, Smith T. Effect of modest vitamin E supplementation on blood glycated hemoglobin and triglycéride levels and red cell indices in type I diabetic patients. J Am Coll Nutr 1996 ; 15:458-61.
48. Paolisso G, D'Amore A, Galzerano D, et al. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 1993 ; 16 : 1433-7.
49. Jain SK, McVie R, Jaramillo JJ, et al. Effect of modest vitamin E supplementation on lipid peroxidation products and other cardiovascular risk factors in diabetic patients. Lipids 1996 ; 31 : S87-90.
50. Chung TW, Hau Yu JJ, Liu DZ. Reducing lipid peroxidation stress of erythrocyte membrane by a-tocopherol nicotinate plays an important role in improving blood Theological properties in type 2 diabetic patients with retinopathy. DiabMed 1998 ; 15 : 380-5.
51. Ziegler D, Hanefeld M, Ruhnau KJ, et al. and the Aladin Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. Diabetologia 1995 ; 38 : 1425-33.
52. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes - induced arterial wall protein crosslinking. Science 1986 ; 232 : 1629-32.
53. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992 ; 15 : 1835-43.
54. Guillausseau PJ. Traitement préventif de la microangiopathie diabé tique : bloquer les mécanismes pathogéniques. Pharmacological prevention of diabetic microangiopathy. Diabète Métab 1994 ; 20 : 219-28.
55. Philis-Tsimikas A, Parthasarathy S, Picard S, Palinski W, Witztum J.L Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. Arterioscler Thromb Vase Biol 1995 ; 15 : 367-76.
56. Lisfi D, Jore D. Bônnefont-Rousselot D, Delattre J, Belâaraj A, Gardes-Albert M. Rôle antioxydant de l'aminoguanidine soumise àl'action des radicaux libres OH et O2 -produits par radiolyse continue de l'eau. J Cliim Phys 1997 ; 94 : 283-8.
57. Picard S, Parthasarathy S, Fruebis J, Witztum JL. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 1992 ; 89 : 6876-80.
58. Giardino I, Fard AK, Hatchell DL, Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation and oxidant-induced apoptosis. Diabetes 1998 ; 47 : 1114-20.